Mette Deleuran
About
Mette Deleuran is a scholar working on Dermatology, Immunology and Allergy and Physiology.
According to data from OpenAlex, Mette Deleuran has authored 179 papers receiving a total of 5.9k indexed citations (citations by other indexed papers that have themselves been cited), including 141 papers in Dermatology, 108 papers in Immunology and Allergy and 47 papers in Physiology. Recurrent topics in Mette Deleuran's work include Dermatology and Skin Diseases (136 papers), Allergic Rhinitis and Sensitization (82 papers) and Food Allergy and Anaphylaxis Research (51 papers). Mette Deleuran is often cited by papers focused on Dermatology and Skin Diseases (136 papers), Allergic Rhinitis and Sensitization (82 papers) and Food Allergy and Anaphylaxis Research (51 papers). Mette Deleuran collaborates with scholars based in Denmark, United States and Germany. Mette Deleuran's co-authors include Christian Vestergaard, Bent Deleuran, Andreas Wollenberg, Alain Taı̈eb, Malene Hvid, Thomas Werfel, Uffe Nygaard, Giampiero Girolomoni, Thomas Bieber and Johannes Ring and has published in prestigious journals such as SHILAP Revista de lepidopterología, The Journal of Immunology and Gut.
In The Last Decade
Mette Deleuran
166 papers receiving 5.7k citations
Hit Papers
Peers
Mette Deleuran
Christian Vestergaard Denmark
Thomas Werfel Germany
Peck Y. Ong United States
Axel Trautmann Germany
Hidehisa Saeki Japan
Didier G. Ebo Belgium
Antti Lauerma Finland
J. Berth‐Jones United Kingdom
Franziska Ruëff Germany
Dagmar Simon Switzerland
Citations per year, relative to Mette Deleuran Mette Deleuran (= 1×)
peers
Christian Vestergaard
Countries citing papers authored by Mette Deleuran
Since
Specialization
Citations
This map shows the geographic impact of Mette Deleuran's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mette Deleuran with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mette Deleuran more than expected).
Fields of papers citing papers by Mette Deleuran
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Mette Deleuran. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mette Deleuran. The network helps show where Mette Deleuran may publish in the future.
Co-authorship network of co-authors of Mette Deleuran
This figure shows the co-authorship network connecting the top 25 collaborators of Mette Deleuran. A scholar is included among the top collaborators of Mette Deleuran based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mette Deleuran. Mette Deleuran is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Cork, Michael J., Mette Deleuran, Bob Geng, et al.. (2025). Long-Term Safety of Abrocitinib in Moderate-to-Severe Atopic Dermatitis: Integrated Analysis by Age. The Journal of Allergy and Clinical Immunology In Practice. 13(5). 1164–1175.e2.
2.
Deleuran, Mette, et al.. (2025). Setting Patient-Centered Treatment Goals in Atopic Dermatitis: Shared Decision and A Treat-to-target Strategy. Current Treatment Options in Allergy. 12(1).
3.
Schmidt, Sigrún Alba Jóhannesdóttir, Dóra Körmendiné Farkas, Mette Deleuran, et al.. (2025). Long‐term socioeconomic outcomes in Danish children with moderate‐to‐severe atopic dermatitis. Journal of the European Academy of Dermatology and Venereology. 40(1). 79–89.
4.
Silverberg, Jonathan I., Melinda Gooderham, Amy S. Paller, et al.. (2024). Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2). American Journal of Clinical Dermatology. 25(3). 485–496.
5.
Beck, Lisa A., Robert Bissonnette, Mette Deleuran, et al.. (2024). Dupilumab in Adults With Moderate to Severe Atopic Dermatitis. JAMA Dermatology. 160(8). 805–805.
6.
Cork, Michael J., et al.. (2023). Dupilumab treatment reduces total IgE levels in patients 6 months and older with moderate-to-severe atopic dermatitis. Revue française d'allergologie. 63(3). 103434–103434.
7.
Reich, Kristian, Marjolein de Bruin‐Weller, Mette Deleuran, et al.. (2023). Higher levels of response on clinical atopic dermatitis severity measures are associated with meaningful improvements in patient‐reported symptom and quality of life measures: Integrated analysis of three Upadacitinib phase 3 trials. Journal of the European Academy of Dermatology and Venereology. 37(8). 1634–1641.
8.
Gerbens, Louise A. A., Phyllis I. Spuls, Soudeh Mashayekhi, et al.. (2023). Phototherapy for atopic dermatitis: A survey of European practice. Journal of the European Academy of Dermatology and Venereology. 38(3). 521–529.
9.
Reich, Kristian, Jonathan I. Silverberg, Kim Papp, et al.. (2023). Abrocitinib effect on patient‐reported outcomes in patients with moderate‐to‐severe atopic dermatitis: Results from phase 3 studies, including the long‐term extension JADE EXTEND study. Journal of the European Academy of Dermatology and Venereology. 37(10). 2047–2055.
10.
Reich, Kristian, Jonathan I. Silverberg, Kim Papp, et al.. (2023). Abrocitinib efficacy and safety in patients with moderate‐to‐severe atopic dermatitis: Results from phase 3 studies, including the long‐term extension JADE EXTEND study. Journal of the European Academy of Dermatology and Venereology. 37(10). 2056–2066.
11.
Vittrup, Ida, Niels Steen Krogh, Jesper Elberling, et al.. (2023). A nationwide 104 weeks real‐world study of dupilumab in adults with atopic dermatitis: Ineffectiveness in head‐and‐neck dermatitis. Journal of the European Academy of Dermatology and Venereology. 37(5). 1046–1055.
12.
Flohr, Carsten, Alan D. Irvine, Michael J. Cork, et al.. (2023). Dupilumab improves patient-reported symptoms and health-related quality of life in children aged 6–11 years with severe atopic dermatitis. British Journal of Dermatology. 189(2). 238–240.
13.
Yosipovitch, Gil, Melinda Gooderham, Sonja Ständer, et al.. (2023). Interpreting the Relationship Among Itch, Sleep, and Work Productivity in Patients with Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of JADE MONO-2. American Journal of Clinical Dermatology. 25(1). 127–138.
14.
Beck, Lisa A., Diamant Thaçi, Mette Deleuran, et al.. (2021). Laboratory safety of dupilumab for up to 3 years in adults with moderate-to-severe atopic dermatitis: results from an open-label extension study. Journal of Dermatological Treatment. 33(3). 1608–1616.
15.
Griffiths, C.E.M., Marjolein de Bruin‐Weller, Mette Deleuran, et al.. (2021). Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four Phase 3 Trials. Dermatology and Therapy. 11(4). 1357–1372.
16.
Gerner, Trine, Christian Vestergaard, Mette Deleuran, et al.. (2020). Healthcare utilization in Danish children with atopic dermatitis and parental topical corticosteroid phobia. Pediatric Allergy and Immunology. 32(2). 331–341.
17.
Alexander, Helen, Amy S. Paller, Claudia Traidl‐Hoffmann, et al.. (2019). The role of bacterial skin infections in atopic dermatitis: expert statement and review from the International Eczema Council Skin Infection Group. British Journal of Dermatology. 182(6). 1331–1342.
18.
Eichenfield, Lawrence F., Thomas Bieber, Lisa A. Beck, et al.. (2019). Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis. American Journal of Clinical Dermatology. 20(3). 443–456.
19.
Gerbens, Louise A. A., Angela L. Bosma, Christian Apfelbacher, et al.. (2019). TRE atment of AT opic eczema ( TREAT ) Registry Taskforce: consensus on how and when to measure the core dataset for atopic eczema treatment research registries. British Journal of Dermatology. 181(3). 492–504.
20.
Saunte, Ditte Marie Lindhardt, Rasmus Krøger Hare, Karin Meinike Jørgensen, et al.. (2019). Emerging Terbinafine Resistance in Trichophyton : Clinical Characteristics, Squalene Epoxidase Gene Mutations, and a Reliable EUCAST Method for Detection. Antimicrobial Agents and Chemotherapy. 63(10).
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Christian Vestergaard Breakdown of academic impact, for papers by Thomas Werfel Breakdown of academic impact, for papers by Peck Y. Ong Breakdown of academic impact, for papers by Axel Trautmann Breakdown of academic impact, for papers by Hidehisa Saeki Breakdown of academic impact, for papers by Didier G. Ebo Breakdown of academic impact, for papers by Antti Lauerma Breakdown of academic impact, for papers by J. Berth‐Jones Breakdown of academic impact, for papers by Franziska Ruëff Breakdown of academic impact, for papers by Dagmar Simon